-
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
20 Apr 2024 12:31 GMT
… lung cancer: current treatment and future advances. Transl Lung Cancer Res … with small-cell lung cancer. Clin Lung Cancer. 2003;5(2 … al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti … . Non-small-cell lung cancers: a heterogeneous set of …
-
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
25 Apr 2024 02:11 GMT
… toripalimab in combination with gemcitabine-cisplatin as the first … non-squamous non-small cell lung cancer (NSCLC);
in combination … tissue sarcoma, and small cell lung cancer (SCLC). In Europe, … combined with cisplatin and gemcitabine for the first-line …
-
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
11 Apr 2024 16:52 GMT
… for non-small-cell lung cancer (NSCLC) patients ineligible … 7,8 of all lung cancers cases, with nearly … the specific proportion of gemcitabine and vinorelbine usage. Consequently … -cell lung cancer: a cost-effectiveness analysis. Translational Lung Cancer Res. …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:50 GMT
… cell lung cancer (ES-SCLC).
IMFINZI, in combination with gemcitabine and … .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … caregivers/lung-cancer-101/types-of-lung-cancer. Accessed …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:27 GMT
… cell lung cancer (ES-SCLC).
IMFINZI, in combination with gemcitabine and … .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … caregivers/lung-cancer-101/types-of-lung-cancer. Accessed …
-
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
04 Apr 2024 11:01 GMT
… non-small cell lung cancers (adenocarcinoma). Despite … been challenging.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … protein-bound, or gemcitabine and carboplatin) were …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… patients with metastatic lung cancer, lung cancer continues to … cycles.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … protein-bound, or gemcitabine and carboplatin) were …
-
FDA Drug Approvals Q1 2024
24 Apr 2024 15:11 GMT
… in combination with cisplatin and gemcitabine for first-line treatment of … approval for non-small cell lung cancer (initially accelerated approval)
Wyost (denosumab …
-
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
21 Mar 2024 11:01 GMT
… non-small cell lung cancer. We sincerely thank … intolerable toxicity.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … in combination with gemcitabine and cisplatin, KEYTRUDA …
-
Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment
24 Apr 2024 07:54 GMT
… various cancers, including hepatocellular carcinoma, lung cancer, and pancreatic cancer. Its antitumor … -responsive artesunatum prodrug nanoassembly potentiates gemcitabine activity by down-regulating CDA …